Table 1.
Baseline characteristics of the cohort
| Variable | Intervention | Control | p |
|---|---|---|---|
| n = 25 | 14 | 11 | - |
| Age (years) | 56.5 (50.75 - 62.25) | 61 (52 - 71) | 0.291* |
| Gender % | - | - | 0.452† |
| Female | 71.42 | 81.81 | - |
| Male | 28.58 | 18.19 | - |
| BMI (kg/m2) | 31.51 (26.62 - 34.77) | 33.32 (26.34 - 37.18) | 0.647* |
| Hypertension % | 100 | 100 | 1† |
| Dysllpldemla % | 71.42 | 72.72 | 0.649† |
| Smoking % | 35.71 | 18.18 | 0.305† |
| Etlology % | - | - | 0.697† |
| Ischemic | 7.14 | 9.09 | - |
| Hypertensive | 92.86 | 90.91 | - |
| Others | 0 | 0 | - |
| Echocardiography | - | - | - |
| LVEF % | 63.5 (60.75 - 72.25) | 67 (54 - 71) | 0.979* |
| E/E' | 16.15 (15.35 - 17.25) | 15.2 (13.88 - 16.9) | 0.183* |
| E/A | 0.41 (0.32 - 0.74) | 0.38 (0.22 - 0.5) | 0.244* |
| LAVI (ml/m2) | 45.26 (41.98 - 48.72) | 40.58 (36.6 - 45.54) | 0.107* |
| LVMI (g/m2) | 124,05(113,5-131,35) | 124 (97.36 - 130) | 0.609* |
| FC /NYHA% | - | - | 0.444† |
| I | 7.15 | 18.18 | - |
| II | 42.85 | 54.54 | - |
| III | 50 | 27.28 | - |
| IV | 0 | 0 | - |
| Medications in use % | - | - | - |
| Beta-blocker | 42.85 | 63.63 | 0.265† |
| Atenolol | 66.66 | 42.85 | - |
| Carvedilol | 33.34 | 42.85 | - |
| Propranolol | 0 | 14.3 | - |
| ACEI/ARA II | 85.71 | 81.81 | 0.604† |
| Hydralazine | 14.28 | 18.18 | 0.604† |
| Nitrate | 14.28 | 36.36 | 0.209† |
| Spironolactone | 14.28 | 27.27 | 0.378† |
| Diuretic | 71.42 | 54.54 | 0.325† |
| Ca channel blocker | 64.28 | 36.36 | 0.163† |
| Clonidine | 42.85 | 27.27 | 0.352† |
| Aspirin | 28.57 | 45.45 | 0.325† |
| Statin | 35.71 | 63.63 | 0.163† |
*
Mann-Whitney U Test;
†
Chi-square test; N: number of patients; BMI: body mass index; LVEF: left ventricular ejection fraction; E/E’: ratio of the mitral peak velocity of early filling to the early diastolic mitral annular velocity; E/A: ratio of the mitral peak velocity of early filling to the mitral peak velocity of late filling; LAVI: left atrial volume index; LVMI: left ventricular mass index; FC: functional class; NYHA: New York Heart Association; ACEI: angiotensin II converting enzyme inhibitor; AAR II: angiotensin II receptor antagonist; Ca: calcium.